Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers
Leubitz, Andi, Frydman‐Marom, Anat, Sharpe, Neal, Duzer, John, Campbell, Kathleen C.M., Vanhoutte, Frédéric
Published in Clinical pharmacology in drug development (01.11.2019)
Published in Clinical pharmacology in drug development (01.11.2019)
Get full text
Journal Article
Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX‐02 in Patients With Nephropathic Cystinosis
Haverty, Thomas, Wyatt, David J., Porter, Kaela M., Leubitz, Andi, Banks, Kate, Goodyer, Paul, Hu, Ming‐Yi
Published in Journal of clinical pharmacology (01.07.2021)
Published in Journal of clinical pharmacology (01.07.2021)
Get full text
Journal Article
A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects
Leubitz, Andi, Vanhoutte, Frederic, Hu, Ming‐yi, Porter, Kaela, Gordon, Efrat, Tencer, Kathleen, Campbell, Kathleen, Banks, Kate, Haverty, Tom
Published in Clinical pharmacology in drug development (01.08.2021)
Published in Clinical pharmacology in drug development (01.08.2021)
Get full text
Journal Article